125552-89-8

Usage

Chemical Properties

Viscous liquid

InChI:InChI=1/C6H11BrO/c7-5-6-1-3-8-4-2-6/h6H,1-5H2

Upstream product

• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 
• 101691-65-0 toluene-4-sulfonic acid tetrahydropyran-4-ylmethyl ester 
• 132291-95-3 4-(methanesulfonyloxymethyl)tetrahydropyran 
• 558-13-4 carbon tetrabromide 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 

Downstream Products

• 850429-50-4 2-(tetrahydro-2H-pyran-4-yl)acetonitrile 
• 174485-18-8 [3-(Cyclopropyl-{4-hydroxy-2-oxo-6-[1-(tetrahydro-pyran-4-ylmethyl)-propyl]-2H-pyran-3-yl}-methyl)-phenyl]-carbamic acid benzyl ester 
• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 130290-79-8 4-tetrahydropyranmethylamine 
• 40500-10-5 3-(tetrahydro-2H-pyran-4-yl)propanoic acid 
• 1822-32-8 3-(4-piperidyl)propionic acid 
• 52601-24-8 1-azabicyclo[2.2.2]octane-2-carboxylic acid 
• 1043908-40-2 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-methyl-1-((tetrahydro-2H-pyran-4-yl)methyl)-3-m-tolyl-1H-imidazol-2(3H)-one 
• 1050495-44-7 2-[(cyclohexylmethyl)oxy]-8-(methoxy)-9-(tetrahydro-2H-pyran-4-ylmethyl)-9H-purin-6-amine 
• 864266-77-3 4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)benzonitrile 
• 1186484-41-2 2-(2,3-Difluoro-phenyl)-5-{6-[4-(tetrahydro-pyran-4-ylmethoxy)-2-trifluoromethyl-phenyl]-pyridazin-3-ylmethyl}-5H-imidazo[4,5-d]pyridazine 
• 1135041-76-7 3-bromo-5-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine 
• 1240494-89-6 N-(4-fluorophenyl)-6-((tetrahydro-2H-pyran-4-yl)methylthio)nicotinamide 

Relevant academic research and scientific papers

NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9

The present invention relates to an inhibitor of cyclin-dependent kinase CDK9, having a structure of formula (I). The present invention also provides a method of treating a cancer of a precancerous condition related to CDK9 activity with the inhibitor and a use of the same.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor

Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.

Pharmaceutical compositions and methods for effecting dopamine release

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.1]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

Adenosine A2A receptor agonists as antiinflammatory agents

The present invention provides compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, together with processes for the preparation of, compositions containing, uses of and intermediates used in the preparation of such compounds that have A2a receptor agonist activity.

Twisted Si=N bonds: Matrix isolation of bridgehead silanimines

We report the IR and UV-vis spectra of three bridgehead silanimines, 1-sila-2-azabicyclo[3.2.2]non-1(2)-ene, 1-sila-2-azabicyclo[3.2.1]oct-1(2)-ene, and 1-sila-2-azabicyclo[2.2.2]oct-1(2)-ene, prepared in matrix isolation by UV irradiation of bridgehead s